Recombinant STEAP1 (Vandortuzumab Biosimilar) antibody
The Human Monoclonal anti-STEAP1 (Vandortuzumab Biosimilar) antibody (ABIN7795150) specifically detects STEAP1 (Vandortuzumab Biosimilar) in FACS and in vivo.
The antibody is reactive with Human samples.
Catalog No. ABIN7795150
-15% Promotion 2026
$310.57
save $54.81 (-15 %)
Plus shipping costs $50.00
1 mg
Shipping to:
United States
Delivery in 21 to 26 Business Days
Quick Overview for Recombinant STEAP1 (Vandortuzumab Biosimilar) antibody (ABIN7795150)
Target
STEAP1 (Vandortuzumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Human
Clonality
Monoclonal
Conjugate
This STEAP1 (Vandortuzumab Biosimilar) antibody is un-conjugated
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Vandortuzumab Biosimilar, Anti-STEAP1 Monoclonal Antibody
-
Characteristics
- The anti-STEAP1 monoclonal antibody vandortuzumab biosimilar was produced in mammalian cells.
-
Purification
- Protein A or G affinity column
-
Purity
- >95 % by reducing SDS-PAGE
-
Endotoxin Level
- < 1 EU per 1 mg of the protein by the LAL method
-
Isotype
- IgG1, kappa
-
-
anti-STEAP1 (Vandortuzumab Biosimilar) antibody
Research Grade Reactivity: Human FACS Host: Humanized Monoclonal unconjugated
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- > 3 mg/mL
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- STEAP1 (Vandortuzumab Biosimilar)
-
Alternative Name
- Vandortuzumab Biosimilar
-
Target Type
- Biosimilar
Target
-
You are here:
